CC趋化因子受体2/单核细胞趋化蛋白1与肾脏疾病的研究进展  

Research advances of CCR2/MCP-1 and kidney diseases

作　　者：沈雁婕 闫莉莉 任振华[1] 鹿玲[2] 张琴[2] Shen Yan-jie;Yan Li-li;Ren Zhen-hua;Lu Ling;Zhang Qin(Neurobiological Institution,Anhui Medical University,Hefei 230032,China;Department of Pediatrics,First Affiliated Hospital,Hefei 230022,China)

机构地区：[1]安徽医科大学神经生物学研究所,合肥230032 [2]安徽医科大学第一附属医院儿科,合肥230022

出　　处：《临床肾脏病杂志》2021年第3期257-261,共5页Journal Of Clinical Nephrology

基　　金：安徽高校自然科学研究项目(KJ2019A0245)。

摘　　要：CC趋化因子受体2(CC chemokine receptor,CCR2)是单核细胞趋化蛋白-1(monocyte chemoattractant protein,MCP-1)的主要受体,可与MCP-1发生特异性结合将信号转入细胞内,趋化并激活单核/巨噬细胞,促进炎症的发生发展。研究表明,CCR2/MCP-1参与了多种肾脏疾病的发展进程,本文就近年来CCR2/MCP-1与肾病研究进展做一综述。As a major receptor of monocyte chemotactic protein-1(MCP-1),CC chemokine receptor 2(CCR2)can specifically conjugate to MCP-1,transfer signals into cytoplasm,mediate the chemotaxis and activation of monocytes and macrophages and promote the occurrence and development of inflammation.Previous studies have shown that CCR2/MCP-1 were involved in the development of many kidney diseases.This review summarized the recent research advances of CCR2/MCP-1 and kidney disease.

关 键 词：CC趋化因子受体2 单核细胞趋化蛋白-1 肾病 

分 类 号：R692[医药卫生—泌尿科学]